Literature DB >> 21139577

Sporadic nonampullary duodenal adenoma in the natural history of duodenal cancer: a study of follow-up surveillance.

Kazuhisa Okada1, Junko Fujisaki, Akiyoshi Kasuga, Masami Omae, Manabu Kubota, Toshiaki Hirasawa, Akiyoshi Ishiyama, Masahiko Inamori, Akiko Chino, Yorimasa Yamamoto, Tomohiro Tsuchida, Atsushi Nakajima, Etsuo Hoshino, Masahiro Igarashi.   

Abstract

OBJECTIVES: Although sporadic nonampullary duodenal adenoma (SNDA) is regarded as a precancerous lesion, its natural course is uncertain. The aim of this study was to evaluate the risk of development of adenocarcinoma in SNDA lesions initially diagnosed as showing low-grade dysplasia (LGD; category 3) or high-grade dysplasia (HGD; category 4.1).
METHODS: We analyzed 68 SNDAs, diagnosed based on initial and subsequent biopsies, in 66 consecutive patients. Of these, 46 (43 LGD lesions, 3 HGD lesions) were followed up for ≥6 months without treatment (mean 27.7±16.9 months; range 6-72 months), including 8 lesions that were eventually resected during follow-up. Sixteen lesions (eight LGD lesions, eight HGD lesions) were resected immediately, either endoscopically or surgically, and six lesions were excluded because of a short follow-up (<6 months). The histopathological diagnoses and macroscopic changes were evaluated.
RESULTS: Among the 43 LGD lesions followed up for ≥6 months, 34 (79.1%) showed no histopathological changes during follow-up, whereas the remaining 9 (20.9%) showed progression to HGD, including 2 (4.7%) that progressed eventually to noninvasive carcinoma (category 4.2). Macroscopically, 76.7% (33 of 43) of the LGD lesions showed no notable changes in size, 16.3% (7 of 43) became undetectable, 4.7% (2 of 43) reduced in size, and 2.3% (1 of 43) became larger in size. In contrast, all the three HGD lesions that were followed up for ≥6 months remained unchanged histologically, based on biopsy, and showed no notable macroscopic changes, although one of these HGD lesions resected endoscopically revealed evidence of noninvasive carcinoma. Although we diagnosed all lesions as HGD from biopsy samples, a high percentage of cancers (54.5%, 6 of 11) were diagnosed from resected specimens. A multivariate analysis identified HGD diagnosed at first biopsy and a lesion diameter of ≥20 mm as being significantly predictive of progression to adenocarcinoma.
CONCLUSIONS: LGD lesions show a low risk of progression to adenocarcinoma, but some risk of progression to HGD, which warrants careful follow-up biopsy. However, HGD lesions and large SNDAs≥20 mm in diameter show a high risk of progression to adenocarcinoma. Therefore, they should be treated immediately.

Entities:  

Mesh:

Year:  2010        PMID: 21139577     DOI: 10.1038/ajg.2010.422

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  43 in total

1.  Treatment of nonampullary sporadic duodenal adenomas with endoscopic mucosal resection or ablation.

Authors:  Ryan Perumpail; Shai Friedland
Journal:  Dig Dis Sci       Date:  2013-10       Impact factor: 3.199

2.  Expression of Gastric Markers Is Associated with Malignant Potential of Nonampullary Duodenal Adenocarcinoma.

Authors:  Chihiro Minatsuki; Nobutake Yamamichi; Ken-Ichi Inada; Yu Takahashi; Kouhei Sakurai; Takeshi Shimamoto; Yosuke Tsuji; Kazuya Shiogama; Shinya Kodashima; Yoshiki Sakaguchi; Keiko Niimi; Satoshi Ono; Toru Niwa; Ken Ohata; Nobuyuki Matsuhashi; Masao Ichinose; Mitsuhiro Fujishiro; Yutaka Tsutsumi; Kazuhiko Koike
Journal:  Dig Dis Sci       Date:  2018-06-28       Impact factor: 3.199

Review 3.  Future directions of duodenal endoscopic submucosal dissection.

Authors:  Satohiro Matsumoto; Hiroyuki Miyatani; Yukio Yoshida
Journal:  World J Gastrointest Endosc       Date:  2015-04-16

4.  Identification of marker genes and pathways specific to precancerous duodenal adenomas and early stage adenocarcinomas.

Authors:  Yoshiki Sakaguchi; Nobutake Yamamichi; Shuta Tomida; Chihiro Takeuchi; Natsuko Kageyama-Yahara; Yu Takahashi; Kazuya Shiogama; Ken-Ichi Inada; Masao Ichinose; Mitsuhiro Fujishiro; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2018-06-28       Impact factor: 7.527

5.  Selection of appropriate endoscopic therapies for duodenal tumors: an open-label study, single-center experience.

Authors:  Satohiro Matsumoto; Yukio Yoshida
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 6.  Endoscopic submucosal dissection for duodenal tumors.

Authors:  Kotaro Shibagaki; Norihisa Ishimura; Yoshikazu Kinoshita
Journal:  Ann Transl Med       Date:  2017-04

7.  Endoscopic resection or surgical management for nonampullary duodenal neoplasms?

Authors:  Joon Sung Kim; Byung-Wook Kim
Journal:  Transl Gastroenterol Hepatol       Date:  2018-05-09

8.  APC:T1556fs and STK11 mutations in duodenal adenomas and adenocarcinomas.

Authors:  Yohei Kojima; Kouki Ohtsuka; Hiroaki Ohnishi; Nobutsugu Abe; Junji Furuse; Takashi Watanabe; Masanori Sugiyama
Journal:  Surg Today       Date:  2018-03-10       Impact factor: 2.549

9.  Endoscopic and surgical management of nonampullary duodenal neoplasms.

Authors:  Michael J Bartel; Ruchir Puri; Bhaumik Brahmbhatt; Wei-Chung Chen; Daniel Kim; Carlos Roberto Simons-Linares; John A Stauffer; Mauricia A Buchanan; Steven P Bowers; Timothy A Woodward; Michael B Wallace; Massimo Raimondo; Horacio J Asbun
Journal:  Surg Endosc       Date:  2018-02-01       Impact factor: 4.584

10.  Relationship between Cancer Diagnosis and Complications Following Pancreatoduodenectomy for Duodenal Adenoma.

Authors:  Nina L Eng; Danielle E Mustin; Brendan P Lovasik; Michael K Turgeon; Adriana C Gamboa; Mihir M Shah; Kenneth Cardona; Juan M Sarmiento; Maria C Russell; Shishir K Maithel; Jeffrey M Switchenko; David A Kooby
Journal:  Ann Surg Oncol       Date:  2020-07-20       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.